The low presentation of MAGEA3 peptides and the absence of NY-ESO1 peptides in the ligandome, despite their known protein expression and immunogenicity in HNSCC, suggest that MAGEA3-targeted vaccines may have reduced efficacy (38–42), and highlights a potential challenge in utilizing NY-ESO1 as a target for immunotherapy in OPSCC. The gene discussed is MAGEA3; the disease is head and neck squamous cell carcinoma.